MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 02-09-2026
Becton, Dickinson and Company Net Income 2011-2026 | BDX
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income Becton, Dickinson and Company
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.68 B | 1.7 B | 1.48 B | 1.78 B | 2.09 B | 874 M | 1.23 B | 311 M | 1.1 B | 976 M | 695 M | 1.18 B | 1.29 B | 1.17 B | 1.27 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.09 B | 311 M | 1.26 B |
Quarterly Net Income Becton, Dickinson and Company
| 2025-Q4 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 382 M | 574 M | 308 M | 303 M | 487 M | 537 M | 281 M | 407 M | 460 M | 509 M | - | 360 M | 454 M | 677 M | - | 525 M | 299 M | 1 B | 128 M | 286 M | 1 B | 278 M | 163 M | 451 M | 278 M | 599 M | -135 M | 594 M | 599 M | -136 M | 327 M | -132 M | -136 M | 562 M | 19 M | 390 M | 562 M | 229 M | 181 M | 62 M | 229 M | 236 M | 301 M | 326 M | 236 M | 271 M | 1.2 B | 302 M | 276 M | 625 M | 881 M | 327 M | 625 M | 263 M | 971 M | 343 M | 263 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.2 B | -136 M | 389 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Medical instruments industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Atrion Corporation
ATRI
|
19.4 M | - | - | $ 810 M |  USA |
 |
Luminex Corporation
LMNX
|
15.2 M | - | - | $ 1.75 B | USA |
 |
Akers Biosciences, Inc.
AKER
|
-17.6 M | - | -9.52 % | $ 20.6 M | USA |
 |
Repligen Corporation
RGEN
|
35.6 M | $ 117.78 | -0.46 % | $ 6.56 M | USA |
 |
Antares Pharma, Inc.
ATRS
|
56.2 M | - | - | $ 955 M | USA |
 |
Ekso Bionics Holdings
EKSO
|
-11.7 M | $ 9.4 | -11.74 % | $ 22.8 M | USA |
 |
Cantel Medical Corp.
CMD
|
13.7 M | - | -1.18 % | $ 3.4 B | USA |
 |
CRH Medical Corporation
CRHM
|
-24.5 M | - | - | $ 282 M | USA |
 |
Hill-Rom Holdings, Inc.
HRC
|
223 M | - | -0.05 % | $ 10.3 B | USA |
 |
Haemonetics Corporation
HAE
|
168 M | $ 56.83 | 1.05 % | $ 2.86 B | USA |
 |
ICU Medical
ICUI
|
732 K | $ 123.31 | -1.53 % | $ 3.04 B | USA |
 |
Varian Medical Systems, Inc.
VAR
|
292 M | - | -0.02 % | $ 16.3 B | USA |
 |
Intuitive Surgical
ISRG
|
2.86 B | $ 452.07 | -2.67 % | $ 161 B | USA |
 |
Harvard Bioscience
HBIO
|
-56.7 M | $ 5.2 | 2.16 % | $ 231 M | USA |
 |
Isoray
ISR
|
-103 M | - | 0.03 % | $ 108 M | USA |
 |
AngioDynamics
ANGO
|
-34 M | $ 10.31 | -13.65 % | $ 421 M | USA |
 |
Repro Med Systems
KRMD
|
-2.64 M | $ 4.32 | 1.17 % | $ 200 M | USA |
 |
AtriCure
ATRC
|
-11.4 M | $ 29.07 | 2.68 % | $ 1.39 B | USA |
 |
Pulse Biosciences
PLSE
|
-72.8 M | $ 23.0 | -0.13 % | $ 1.55 B | USA |
 |
InfuSystem Holdings
INFU
|
18 K | $ 9.29 | -0.11 % | $ 192 M | USA |
 |
Masimo Corporation
MASI
|
-305 M | $ 178.59 | 0.33 % | $ 9.52 B | USA |
 |
iRhythm Technologies
IRTC
|
-44.6 M | $ 116.8 | -1.2 % | $ 3.74 B | USA |
 |
Merit Medical Systems
MMSI
|
128 M | $ 67.7 | -0.78 % | $ 4 B | USA |
 |
BioLife Solutions
BLFS
|
-20.2 M | $ 19.51 | 1.14 % | $ 899 M | USA |
 |
electroCore
ECOR
|
-14 M | $ 6.8 | 3.03 % | $ 57.7 K | USA |
 |
STERIS plc
STE
|
615 M | $ 218.71 | -0.56 % | $ 21.6 B | USA |
 |
Teleflex Incorporated
TFX
|
-714 M | $ 117.81 | -0.52 % | $ 5.26 B | USA |
 |
Utah Medical Products
UTMD
|
2.56 M | $ 63.12 | 0.4 % | $ 205 M | USA |
 |
OraSure Technologies
OSUR
|
-68.7 M | $ 3.08 | 0.98 % | $ 226 M | USA |
 |
West Pharmaceutical Services
WST
|
494 M | $ 254.8 | 0.82 % | $ 18.4 B | USA |
 |
DENTSPLY SIRONA
XRAY
|
-598 M | $ 11.63 | -0.26 % | $ 2.32 B | USA |
 |
Glaukos Corporation
GKOS
|
-135 M | $ 112.77 | 0.12 % | $ 5.46 B | USA |
 |
ResMed
RMD
|
779 M | $ 224.09 | 0.56 % | $ 32.7 B | USA |
 |
Predictive Oncology
POAI
|
-233 M | - | - | $ 31.1 M | USA |
 |
Baxter International
BAX
|
-957 M | $ 16.68 | -0.6 % | $ 8.56 B | USA |
 |
NeuroMetrix
NURO
|
-7.81 M | - | 5.05 % | $ 9.02 M | USA |
 |
STAAR Surgical Company
STAA
|
-80.4 M | $ 20.21 | 4.55 % | $ 1 B | USA |
 |
Stereotaxis
STXS
|
-21.6 M | $ 1.87 | 1.08 % | $ 170 M | USA |
 |
The Cooper Companies
COO
|
375 M | $ 70.17 | -1.76 % | $ 14 B | USA |
 |
LeMaitre Vascular
LMAT
|
57.7 M | $ 108.49 | -0.24 % | $ 2.46 B | USA |
 |
Microbot Medical
MBOT
|
-13.1 M | $ 2.4 | 1.27 % | $ 110 M |  Israel |
 |
Nephros
NEPH
|
-1.58 M | $ 2.87 | -2.21 % | $ 29.8 M | USA |
 |
Envista Holdings Corporation
NVST
|
47 M | $ 25.81 | -0.35 % | $ 4.34 B | USA |
 |
Milestone Scientific
MLSS
|
-5.72 M | $ 0.28 | -4.86 % | $ 23 M | USA |
 |
Alcon
ALC
|
376 M | $ 74.56 | -1.26 % | $ 40.4 B |  Schweiz |
 |
Pro-Dex
PDEX
|
8.98 M | $ 51.67 | 1.33 % | $ 170 M | USA |
 |
Retractable Technologies
RVP
|
-12.6 M | $ 0.69 | 2.99 % | $ 20.7 M | USA |